{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:40:08Z","timestamp":1786992008433,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jdiacomp.2023.108405","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T21:04:40Z","timestamp":1673643880000},"page":"108405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes"],"prefix":"10.1016","volume":"37","author":[{"given":"Michelle D.","family":"Lundholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta R.","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2023.108405_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0015","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","author":"Dyson","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0000000000002507","article-title":"The ILTS consensus conference on NAFLD\/NASH and liver transplantation: setting the stage","volume":"103","author":"Burra","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0030","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/TP.0b013e31827afb3a","article-title":"Evolving frequency and outcomes of liver transplantation based on etiology of liver disease","volume":"95","author":"Singal","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0035","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the Most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0040","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0045","doi-asserted-by":"crossref","DOI":"10.2337\/dc15-0078","article-title":"Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry","volume":"38","author":"Miller","year":"2015","journal-title":"Diab Care"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diab Care."},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0055","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.2337\/dc20-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical Care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diab Care."},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"9","year":"2016","journal-title":"Obes Facts"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0065","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0070","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0075","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jhep.2010.04.030","article-title":"Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes","volume":"53","author":"Targher","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0080","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1210\/clinem\/dgaa575","article-title":"Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"105","author":"de Vries","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0085","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eprac.2022.01.008","article-title":"Prevalence and clinical determinants of obesity in adults with type 1 diabetes mellitus: a single-center retrospective observational study","volume":"28","author":"Tsushima","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0090","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0095","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jgh.13814","article-title":"Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes","volume":"33","author":"Sviklane","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0105","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cgh.2016.03.034","article-title":"Development and validation of the Framingham steatosis index to identify persons with hepatic steatosis","volume":"14","author":"Long","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.10.011","article-title":"The ability of the Framingham steatosis index (FSI) to predict non-alcoholic fatty liver disease (NAFLD): a cohort study","volume":"45","author":"Motamed","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0115","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0120","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0125","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0130","first-page":"122","article-title":"Evaluation of diagnostic accuracy of APRI for prediction of fibrosis in hepatitis C patients","volume":"20","author":"Khan","year":"2008","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0135","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0140","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0145","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hep.29113","article-title":"Liver fibrosis scores predict liver disease mortality in the United States population","volume":"66","author":"Unalp-Arida","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jhep.2019.04.020","article-title":"New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD","volume":"71","author":"Boursier","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0175","doi-asserted-by":"crossref","first-page":"e2008","DOI":"10.1210\/clinem\/dgab933","article-title":"Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease","volume":"107","author":"Qadri","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0180","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/gast.2002.35354","article-title":"The utility of radiological imaging in nonalcoholic fatty liver disease","volume":"123","author":"Saadeh","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement","volume":"71","author":"Athyros","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0190","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep."},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0195","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0200","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0205","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0210","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0215","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/hep.30670","article-title":"Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"69","author":"Cusi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jdiacomp.2007.02.005","article-title":"Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes","volume":"21","author":"Lingvay","year":"2007","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0230","doi-asserted-by":"crossref","first-page":"E829","DOI":"10.1152\/ajpendo.00133.2006","article-title":"Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes","volume":"292","author":"Juurinen","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2023.108405_bb0235","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/dom.12751","article-title":"Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes","volume":"18","author":"Cusi","year":"2016","journal-title":"Diabetes Obes Metab."}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687272300003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687272300003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:16:52Z","timestamp":1761005812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105687272300003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S105687272300003X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108405","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023","name":"copyright","label":"Copyright"}],"article-number":"108405"}}